Acetylon Pharmaceuticals, a Boston, MA-based developer of small molecule drugs to realize the therapeutic potential of HDAC inhibition to treat cancer, autoimmune and other diseases, has received a $15m investment from Celgene Corporation (NASDAQ: CELG) in Series B round.
In conjunction with the transaction, Mark Alles, Celgene’s Chief Commercial Officer, will serve as a non-voting observer to the the company’s Board of Directors.
Led by President and CEO Walter C. Ogier, Acetylon is currently focused on the development of potential drug candidates based on next-generation Class II-selective histone deacetylase (HDAC) inhibitors. Its Class IIB enzyme, HDAC6, has emerged as an important target in inflammatory disease, neurologic disease and broadly in cancer.
The company is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University.